Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis

M. E. Sanders, C. L. Koski, D. Robbins, M. L. Shin, M. M. Frank, K. A. Joiner

Research output: Contribution to journalArticle

137 Scopus citations

Abstract

A quantitative enzyme-linked immunosorbent assay was used to measure the concentration of fluid-phase complement C5b-9 complexes (SC5b-9) in the cerebrospinal fluid (CSF) of 14 patients with acute monophasic Guillain-Barre Syndrome (GBS), 21 patients with multiple sclerosis (MS), and 11 patients with noninflammatory central nervous system (CNS) diseases. SC5b-9 complexes were detected in the CSF of 13 of 14 patients with acute GBS (mean, 3.08 μg/ml; range, 0 to 7.1 μg/ml) and 16 of 21 patients with MS (mean, 1.83 μg/ml; range, 0 to 7.5 μg/ml). In the control group of patients with noninflammatory CNS diseases, SC5b-9 was not detected in eight of 11 and was present in low concentrations in the remaining three patients (mean, 0.28 μg/ml; range, 0 to 1.7 μg/ml). The finding of SC5b-9 complexes in the CSF of patients with GBS and MS suggests that terminal complement components may participate in the tissue-damaging processes in these diseases.

Original languageEnglish (US)
Pages (from-to)4456-4459
Number of pages4
JournalJournal of Immunology
Volume136
Issue number12
StatePublished - Aug 27 1986
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this

    Sanders, M. E., Koski, C. L., Robbins, D., Shin, M. L., Frank, M. M., & Joiner, K. A. (1986). Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis. Journal of Immunology, 136(12), 4456-4459.